
KOD Stock Forecast & Price Target
KOD Analyst Ratings
Bulls say
Kodiak Sciences Inc has made significant advancements with its Antibody Biopolymer Conjugate (ABC) platform, leading to promising investigational therapies such as tarcocimab tedromer (Zenkuda) and KSI-501. Recent data from pivotal trials indicated that KSI-101 achieved over 90% of patients reaching retinal dryness by Week 8 and demonstrated meaningful vision gains, while tarcocimab's strong performance led to increased probabilities of success (POS) for both diabetic retinopathy and wet AMD. With a solid trial execution and positive trends in patient outcomes, the outlook for Kodiak Sciences remains favorable, particularly as the company is poised to release further results from upcoming Phase 3 trials.
Bears say
Kodiak Sciences Inc. faces significant challenges stemming from previous clinical trial failures, including the Phase 3 GLEAM and GLIMMER trials for diabetic macular edema (DME) and the Phase 2b/3 DAZZLE trial for wet age-related macular degeneration (AMD), which have undermined investor confidence. The company's investigational therapies, tarcocimab tedromer and KSI-501, may struggle to achieve peak commercial revenue projections due to concerns regarding market size, penetration rates, and pricing dynamics, resulting in uncertainty around their long-term viability. Additionally, potential difficulties in securing necessary capital to support ongoing development and commercialization efforts further exacerbate the negative outlook for Kodiak Sciences's stock.
This aggregate rating is based on analysts' research of Kodiak Sciences Inc and is not a guaranteed prediction by Public.com or investment advice.
KOD Analyst Forecast & Price Prediction
Start investing in KOD
Order type
Buy in
Order amount
Est. shares
0 shares